Japanese Lung Cancer Registry Study: First Prospective Enrollment of a Large Number of Surgical and Nonsurgical Cases in 2002 Noriyoshi Sawabata, MD,

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Surgical Intervention for Non–Small-Cell Lung Cancer Patients with Pleural Carcinomatosis: Results From the Japanese Lung Cancer Registry in 2004 Tomohiko.

Diagnostic Surgical Pathology in Lung Cancer

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers Hisao Asamura, MD, Tomoyuki Goya, MD, Yoshihiko Koshiishi, MD, Yasunori.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Results of Surgical Treatment for Patients with Small Cell Lung Cancer

Yih-Leong Chang, MD, Chen-Tu Wu, MD, Yung-Chie Lee, MD, PhD

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Surgical Management of Recurrent Thymic Epithelial Tumors: A Retrospective Analysis Based on the Japanese Nationwide Database Tetsuya Mizuno, MD, Meinoshin.

Thymoma—A Clinico-Pathological Long-Term Study with Emphasis on Histology and Adjuvant Radiotherapy Dose Thomas Harnath, MD, Alexander Marx, MD, Philipp.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study: Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category?

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Phase I and Pharmacokinetic Study of Combination Chemotherapy Using Irinotecan and Paclitaxel in Patients with Lung Cancer Gyo Asai, MD, PhD, Nobuyuki.

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study: Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category?

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Pulmonary Resection in Patients Aged 80 Years or Over with Clinical Stage I Non-small Cell Lung Cancer: Prognostic Factors for Overall Survival and Risk.

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Nabil P. Rizk, MD, Venkatraman E. Seshan, PhD, Manjit S

The IASLC Lung Cancer Staging Project: Proposals for the Inclusion of Broncho- Pulmonary Carcinoid Tumors in the Forthcoming (Seventh) Edition of the TNM.

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Clinical Relevance of Our Multimodality Prognostic Score

Validation of the Proposed International Association for the Study of Lung Cancer Non- small Cell Lung Cancer Staging System Revisions for Advanced Bronchioloalveolar.

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival: Its Implications for the Forthcoming TNM Staging Based on a Large-Scale.

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD,

Innovative techniques for thoracoscopic lobectomy in postpneumonectomy patients Ryoichi Nakanishi, MD, PhD, Shinji Shinohara, MD, Kenji Muranaka, MD,

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Lobe-Specific Nodal Dissection for Clinical Stage I and II NSCLC: Japanese Multi- Institutional Retrospective Study Using a Propensity Score Analysis

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

S-1 Treatment for Chemorefractory Thymic Carcinoma

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non–Small Cell Lung Cancer

Japanese Lung Cancer Registry Study of 11,663 Surgical Cases in 2004: Demographic and Prognosis Changes Over Decade Noriyoshi Sawabata, MD, PhD, Etsuo.

Jamie E. Chaft, MD, Camelia S. Sima, MD, MS, Michelle S

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Time Trends of Surgical Outcome in Patients with Non-small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Tetsuro Baba, MD, PhD, Tetsuya So, MD, PhD, Manabu.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

A Review of First-Line Treatment for Small-cell Lung Cancer

Mark A. Socinski, MD Journal of Thoracic Oncology

Visceral Pleural Invasion Classification in Non–Small-Cell Lung Cancer in the 7th Edition of the Tumor, Node, Metastasis Classification for Lung Cancer:

Presentation transcript:

Japanese Lung Cancer Registry Study: First Prospective Enrollment of a Large Number of Surgical and Nonsurgical Cases in 2002 Noriyoshi Sawabata, MD, PhD, Hisao Asamura, MD, PhD, Tomoyuki Goya, MD, PhD, Masaki Mori, MD, PhD, Yoichi Nakanishi, MD, PhD, Kenji Eguchi, MD, PhD, Yoshihiko Koshiishi, MD, PhD, Meinoshin Okumura, MD, PhD, Etsuo Miyaoka, PhD, Yoshitaka Fujii, MD, PhD Journal of Thoracic Oncology Volume 5, Issue 9, Pages 1369-1375 (September 2010) DOI: 10.1097/JTO.0b013e3181e452b9 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 A and B, Survival curves by histology. The 5-year survival rates for NSCLC and SCLC are 46.8% and 14.7%, respectively. The 5-year survival rates and p values are shown in Table 4. NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; AD, adenocarcinoma; SQ, squamous cell carcinoma; ADSQ, adenosquamous cell carcinoma; LA, large cell carcinoma. Journal of Thoracic Oncology 2010 5, 1369-1375DOI: (10.1097/JTO.0b013e3181e452b9) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Clinical stage-specific survival curves for patients with (A) non-small cell carcinoma and (B) small cell carcinoma, by clinical stage. The 5-year survival rates and p values are shown in Table 5. Journal of Thoracic Oncology 2010 5, 1369-1375DOI: (10.1097/JTO.0b013e3181e452b9) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 A and B, Survival curves by treatment. The 5-year survival rates for surgical and nonsurgical cases are 66.0% and 8.5%, respectively. The 5-year survival rates and p values are shown in Table 6. CTx, chemotherapy; RTx, radiotherapy; SC, supportive care including chest drainage and pleurodesis. Journal of Thoracic Oncology 2010 5, 1369-1375DOI: (10.1097/JTO.0b013e3181e452b9) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Stage-specific survival curves for surgical cases by pathologic stage. The 5-year survival rates and p values are shown in Table 10. Journal of Thoracic Oncology 2010 5, 1369-1375DOI: (10.1097/JTO.0b013e3181e452b9) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions